vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $395.6M, roughly 1.6× Dolby Laboratories, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 24.0%, a 10.4% gap on every dollar of revenue. On growth, Dolby Laboratories, Inc. posted the faster year-over-year revenue change (7.1% vs 4.8%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (13.9% CAGR vs 4.6%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
DLB vs RPRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $622.0M |
| Net Profit | $94.9M | $214.2M |
| Gross Margin | 88.7% | — |
| Operating Margin | 28.5% | 62.4% |
| Net Margin | 24.0% | 34.4% |
| Revenue YoY | 7.1% | 4.8% |
| Net Profit YoY | 3.4% | 2.9% |
| EPS (diluted) | $0.99 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $622.0M | ||
| Q3 25 | $307.0M | $609.3M | ||
| Q2 25 | $315.5M | $578.7M | ||
| Q1 25 | $369.6M | $568.2M | ||
| Q4 24 | $357.0M | $593.6M | ||
| Q3 24 | $304.8M | $564.7M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $214.2M | ||
| Q3 25 | $49.3M | $288.2M | ||
| Q2 25 | $46.1M | $30.2M | ||
| Q1 25 | $91.8M | $238.3M | ||
| Q4 24 | $67.8M | $208.2M | ||
| Q3 24 | $58.6M | $544.0M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 86.1% | — | ||
| Q1 25 | 90.3% | — | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 88.8% | — |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 62.4% | ||
| Q3 25 | 9.7% | 70.1% | ||
| Q2 25 | 15.1% | 36.3% | ||
| Q1 25 | 29.2% | 94.0% | ||
| Q4 24 | 22.4% | 60.9% | ||
| Q3 24 | 15.2% | — |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 34.4% | ||
| Q3 25 | 16.1% | 47.3% | ||
| Q2 25 | 14.6% | 5.2% | ||
| Q1 25 | 24.8% | 41.9% | ||
| Q4 24 | 19.0% | 35.1% | ||
| Q3 24 | 19.2% | 96.3% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $0.49 | ||
| Q3 25 | $0.50 | $0.67 | ||
| Q2 25 | $0.48 | $0.07 | ||
| Q1 25 | $0.94 | $0.55 | ||
| Q4 24 | $0.70 | $0.46 | ||
| Q3 24 | $0.59 | $1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $2.6B | $9.7B |
| Total Assets | $3.2B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $618.7M | ||
| Q3 25 | $702.6M | $938.9M | ||
| Q2 25 | $699.3M | $631.9M | ||
| Q1 25 | $626.6M | $1.1B | ||
| Q4 24 | $520.8M | $929.0M | ||
| Q3 24 | $482.0M | $950.1M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.6B | $9.5B | ||
| Q1 25 | $2.6B | $9.8B | ||
| Q4 24 | $2.5B | $10.3B | ||
| Q3 24 | $2.5B | $10.3B |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $19.6B | ||
| Q3 25 | $3.2B | $19.3B | ||
| Q2 25 | $3.2B | $18.3B | ||
| Q1 25 | $3.2B | $17.6B | ||
| Q4 24 | $3.2B | $18.2B | ||
| Q3 24 | $3.1B | $18.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.55× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $827.1M | ||
| Q3 25 | $472.2M | $702.6M | ||
| Q2 25 | $67.7M | $364.0M | ||
| Q1 25 | $174.9M | $596.1M | ||
| Q4 24 | $106.8M | $742.5M | ||
| Q3 24 | $327.3M | $703.6M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | — | ||
| Q3 25 | $435.9M | — | ||
| Q2 25 | $61.3M | — | ||
| Q1 25 | $168.0M | — | ||
| Q4 24 | $100.0M | — | ||
| Q3 24 | $297.2M | — |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 142.0% | — | ||
| Q2 25 | 19.4% | — | ||
| Q1 25 | 45.5% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 97.5% | — |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 9.8% | — |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | 3.86× | ||
| Q3 25 | 9.57× | 2.44× | ||
| Q2 25 | 1.47× | 12.06× | ||
| Q1 25 | 1.91× | 2.50× | ||
| Q4 24 | 1.57× | 3.57× | ||
| Q3 24 | 5.59× | 1.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
